icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 22-25, 2016, Boston MA
Back grey_arrow_rt.gif
 
 
 
Safety and Tolerability of Elbasvir/Grazoprevir in Patients With
Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials
 
 
  Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
 
Sulkowski M1; Dusheiko GM2; Manns MP3; Vierling JM4; Reddy KR5; Kwo P6; Lawitz E7; Brown DD8; Klopfer SO8; Robertson M8; Wahl J8; Barr E8; Haber B8; Charles ED8* 1Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2University College London, Institute of Liver and Digestive Health, Royal Free Hospital, London, UK; 3Medical School of Hannover, Hannover, Germany; 4Baylor St. Luke's Medical Center, Houston, TX, USA; 5University of Pennsylvania, Philadelphia, PA, USA; 6Indiana University School of Medicine, Indianapolis, IN, USA; 7The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 8Merck & Co., Inc., Kenilworth, NJ, USA. *Former employee of Merck & Co., Inc.

CROI1

CROI2

CROI3

CROI4

CROI5

CROI6

CROI7

CROI8

CROI9